SSTR2 Antibodies

Somatostatin receptor type 2 (SSTR2)

Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase.

In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels.

Gene Information

Human
Gene Name:	SSTR2
Uniprot:	P30874
Entrez:	6752

Family

Belongs to:
G-protein coupled receptor 1 family

Alternative Names

Smstr2; Somatostatin R2; somatostatin receptor 2; somatostatin receptor type 2; SomatostatinR2; SRIF-1; SS2R; SS-2-R; SS2-R; SST2; SSTR2

Molecular Weight

Mass (kDA):
41.333 kDA

Genomic Context

Human
Location:	17q25.1
Sequence:	17; NC_000017.11 (73165010..73176633)

Tissue Specificity

Expressed in both pancreatic alpha- and beta- cells (at protein level). Expressed at higher levels in the pancreas than other somatostatin receptors. Also expressed in the cerebrum and kidney and, in lesser amounts, in the jejunum, colon and liver. In the developing nervous system, expressed in the cortex where it is located in the preplate at early stages and is enriched in the outer part of the germinal zone at later stages. In the cerebellum, expressed in the deep part of the external granular layer at gestational week 19. This pattern persists until birth but disappears at adulthood.

Subcellular Localizations

Cell membrane; Multi-pass membrane protein. Cytoplasm. Located mainly at the cell surface under basal conditions. Agonist stimulation results in internalization to the cytoplasm.

Diseases

• Neoplasms
• Pituitary Diseases
• Malignant Neoplasms
• Adenoma
• Carcinoma
• Pituitary Neoplasms
• Pancreatic Neoplasm
• Pituitary Adenoma
• Neuroendocrine Tumors
• Pertussis
• Acromegaly
• Neoplasm Metastasis

• Malignant Paraganglionic Neoplasm
• Carcinoid Tumor
• Growth Hormone-secreting Pituitary Adenoma
• Mammary Neoplasms
• Prolactinoma
• Nervousness
• Malignant Neoplasm Of Breast

Interacting Proteins

• PIK3R1
• SSTR3

Pathways

• Secretion
• Cell Proliferation
• Localization
• Hormone Secretion
• Cell Growth
• Acid Secretion
• Insulin Secretion
• Gastric Acid Secretion
• Angiogenesis
• Cell Cycle
• Growth Hormone Secretion
• Glucagon Secretion
• Cell Cycle Arrest

• Reverse Transcription
• Regulation Of Growth
• Transport
• Endocytosis
• Cellular Localization
• Excretion
• Regulation Of Gastric Acid Secretion

PTMs

• Phosphorylation
• Cleavage
• Demethylation

• Biotinylation
• Glycosylation
• Methylation

Research Areas

• Alzheimers Research
• Cancer
• GPCR
• Neuronal Cell Markers
• Neuroscience

• Neurotransmission

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SSTR2

Best Uses Of The SSTR2 Marker

Researchers in the study of neuroendocrine cancers can use the SSTR2 marker as a valuable tool. It is an excellent tool to identify neuroendocrine tumours, especially when treating melanoma. Researchers using this marker can easily submit results for special species and applications. They can also earn credit for using this product. Scientists worldwide can use this marker.

Xencor announces the second drop in data regarding neuroendocrine cancers

Xencor, Inc., a clinical-stage biopharmaceutical firm, focuses on engineered monoclonal antibodies and cytokine therapies. It is best known for its antibody against the SARS-2 virus, XmAb841. The company announced that it would end clinical development of the drug along with Keytruda in late January. The company said it would continue supporting patients currently enrolled on the trial.

Xencor's recent second-quarter data on neuroendocrine tumors may prove to be helpful for the company's investors. To discuss its results, the company plans to hold a conference calling. The company has requested that the call be recorded. Charles Liles, head of investor relations for the company, will be on the call. He will discuss company progress during the first quarter of 2022.

Xencor has been faced with numerous risks in its research and development programs, including the failure of its product candidates to achieve the anticipated results. These risks are described in the company’s annual reporting. The company warns investors that forward-looking information is subject to risks and uncertainty, and that actual results and performance may differ materially. While Xencor strives to minimize these risks, it is still not immune to unexpected events.

Benefits of using the SSTR2 Marker

Clinical trials have shown that SSTR2 expression is associated to better survival. The marker can be used in targeted therapy for cancer patients. The SSTR2 marker was recently used in PET-CT imaging of NPC patients and revealed its role in the disease. The SSTR2 marker also plays a role in infection, and its expression correlates with improved survival. This marker is being used in clinical trials to treat EBV-associated NPC and to predict patient outcomes following targeted therapy.

The SSTR2 marker has been used in PRRT for over two decades. The pharmacokinetics of this radiopharmaceutical has been improved by conjugating it with a peptide. This ligand has an extended half-life than other PRRT drugs and can be used to treat established SSTR2-positive cancers. Recent research found that 90Y was able to radiotherapy SSTR2+ tumors six times faster than its counterpart TATE. It also possessed superior tumor to non-tumor contrast compared to TATE.

The SSTR2 peptide is a regulatory protein that is abundant in different tissues. It is involved in many cellular functions. SSTR2 regulates synaptic responses by interfacing with inhibitory G–proteins in neurons. The SSTR2 marker has also been shown to control the proliferation of normal and neoplastic cells. It is highly expressed on plasma membrane and has been examined for its potential as prognostic markers in certain cancers.

The expression of SSTR2 has also been investigated in NENs. SSTR proteins can be identified in tumor tissue by immunohistochemistry. However, very few studies have investigated the immunohistochemical reaction of SSTR2 within gastrointestinal NENs. This method is useful in determining the effectiveness of somatostatin alogue treatment. SSTR2 and SSTR5 IHC markers are significant indicators of gastrointestinal cancer.

History of Steven Boster

You can find out more about Steve Boster at many places. His public records include his current address, past addresses, mobile numbers, and email addresses. He also had close friends and relatives. There are also ways to filter Steve Boster's public records by age and state. You can even get a complete overview of Boster’s criminal history. Here are some of the most interesting information you can find about Steve Boster.

Steve Boster, a Joliet native, was born June 6, 1920 and died June 6, 2022. He was a manager of retail sales for many years and was a member of Concordia Hall of Staunton. His two daughters, Crystal Boster (Daughter Natosha) and Crystal Peck (Daughter Natosha) are his survivors. He also has six grandchildren. He is also survived 4 brothers, Jack Boster & Sandra Blanton. There are also many nieces or nephews.

Primary antibodies of high-affinity

SCLC patients are at risk for death if they express SSTR2. High-affinity prima antibodies that target this marker have the potential to be a valuable tool for early diagnosis and treatment. This marker has not been targeted by any approved antibodies. Despite promising results, more research is needed in order to determine the exact mechanism of action for SSTR2 or its ligands.

To use the SSTR2 markers, cells were spiked in healthy donor blood. The antibodies were detected using different exposure times and concentrations. This was done using the CellSearch CTC Kit. The samples were scanned using the Analyzer II, a CellTracks autoprep kits, and the CTC kit. After scanning the samples, the positive cells in the samples were counted. Their numbers were then compared with the expected values, based on their transfection rate.

SSTR2 gene also contains two distinct subtypes. SSTR2A has a carboxyl terminus sequence that differs from SSTR2B, while SSTR2B contains only one variant. The PEN-221 assay measures the effects of PEN-221 bind to SSTR2 internalization. It uses human tissues for the production of a soluble fraction of human SSTR2 Protein.

SSTR2 expression is found in various types of tumors, including pancreatics, gastrics, and intestine. The sstr2A subtype, which is found in a lower proportion of pancreatic cancers, such as insulinomas, is expressed. Despite its high expression, it doesn't appear to be a determinant of neuroendocrine tumors. SS2 subtypes are also low in expression in a variety types of tumors.